U.S. FDA approves Novartis therapy for prostate cancer
(Reuters) -The U.S. Meals and Drug Administration accredited Novartis AG’s remedy for the remedy of sufferers with a sort of superior prostate most cancers that has unfold to different components of the physique, the drugmaker stated on Wednesday.
Novartis’ Pluvicto is a focused radioligand remedy for grownup sufferers who’ve already undergone different anticancer remedies.
The corporate purchased the remedy as a part of its $2.1 billion buy of most cancers drugmaker Endocyte in 2018.
Pluvicto is a precision remedy combining a concentrating on compound, or ligand, with a cancer-killing radioactive particle, Novartis stated.
The corporate stated it has submitted advertising and marketing authorization for Pluvicto to the European Medicines Company and different well being authorities.
Two late-stage research evaluating Pluvicto in earlier traces of remedy for metastatic prostate most cancers are underway, in accordance with Novartis.
(Reporting by Manojna Maddipatla in Bengaluru; Modifying by Shounak Dasgupta)